Request a Quote

Leadership

Management Team

Tracy Wilson Curley

Interim Chief Executive Officer & Chief Financial Officer

Tracy Wilson Curley

Interim Chief Executive Officer & Chief Financial Officer

Tracy is an experienced, results-oriented business builder focused on leading iSpecimen’s vision for progressive financial performance, expansion and growth in today’s dynamic healthcare and biotechnology research markets.

Tracy brings three decades of experience in public accounting and corporate finance for both publicly traded companies and emerging companies like iSpecimen. Before joining iSpecimen, Tracy served as a partner at CohnReznick LLP, a national accounting firm, where she led the creation and development of an emerging markets commercial audit practice team focused on recruiting and providing audit services to private and public emerging growth companies in the technology and life sciences industries. Earlier, and as a partner at Marcum LLP, a national accounting firm, Tracy led the northeast regional high-tech practice for the firm with a focus on expanding the client base to provide a full range of accounting, tax and advisory services for private and public emerging growth companies in high tech industries such as technology, life sciences and advanced manufacturing. Tracy has also served as a partner at Moody, Famiglietti & Andronico, LLP (MFA), a proactive, Boston-based consulting firm with national and global reach, where she led the creation and development of a public company audit practice focused on recruiting and providing audit services to public emerging growth companies.

Tracy received her Master of Accountancy and Bachelor of Science in Business Administration with a concentration in accounting from Kansas State University. She also attended the United States Military Academy. She is a certified public accountant licensed in the Commonwealth of Massachusetts.

Man smiling closeup

Benjamin Bielak

Chief Information Officer

Man smiling closeup

Benjamin Bielak

Chief Information Officer

Ben brings 25 plus  years of executive and senior information technology experience to iSpecimen. In his role at iSpecimen as Chief Information Officer, Ben is responsible for technology delivery and data strategy and services.  He most recently served as the Chief Information Officer at GNS Healthcare, a leading casual machine learning product and services company, and as Director of Academic Technology at Harvard University. Prior to his work at GNS and Harvard, Bielak was the Chief Information Officer at Dovetail Health, a high-growth product and services company focused on reducing costs through pharmacy-focused interventions. He previously held roles as Manager of Development and Integration at Boston Medical Center and Senior Manager of Technology at Sapient.

Bielak holds a Master of Business Administration degree from Bentley University, where his studies focused on change management, and a master’s degree from Boston University in computer science. He maintains two certifications, the College of Healthcare Information Management Executives (CHIME) Certified Healthcare Chief Information Officer (CHCIO) and the Health Information Management System Society (HIMSS) Certified Professional in Healthcare Information and Management Systems (CPHIMS).

David_Wages_2017_ 757

David Wages, MD, PhD

Chief Medical Officer

David_Wages_2017_ 757

David Wages, MD, PhD

Chief Medical Officer

David is responsible for ensuring that iSpecimen meets the medical research needs of customers. This includes ensuring that specimens are of the highest quality and that iSpecimen technology will continue to meet the increasingly sophisticated needs of the academic, pharmaceutical, and government research communities.

Prior to joining iSpecimen, David served as Senior Medical Director at Quintiles, the world’s largest clinical research organization, where he supported both large pharmaceutical companies as well as smaller biotech organizations in a wide variety of clinical oncology programs. David has worked in both start-up biotechs and large pharma. David began his career working on the clinical development of novel drug-device combinations for blood decontamination at Cerus Corporation. He then worked on clinical trials at Wyeth that led to the development of Xyntha®, a drug used to treat hemophilia. After a brief stint assisting institutional investors on healthcare technology opportunities at Leerink-Swann’s Medacorp, David then moved on to ARIAD Pharmaceuticals where he turned to cancer research, working on ARIAD’s mTOR inhibitor for solid tumors as well as initiating ARIAD’s phase I trial for chronic myeloid leukemia drug, Iclusig®. David next joined EMD Serono where he worked on phase I-III trials of immune-agents for oncology. David holds an MD and PhD from the University of Virginia School of Medicine where he focused on the basic science of oncology. He then completed a residency at the University of California, San Francisco and a fellowship in hematopathology at Boston’s Beth Israel hospital.

Eric Langlois

Eric Langlois

Senior Vice President of Sales & Business Development

Eric Langlois

Eric Langlois

Senior Vice President of Sales & Business Development

Eric is responsible for driving and managing all aspects of company sales and business development. In this position, he applies his strategic vision as well as day-to-day execution on initiatives related to revenue generation and account management.  He also plays a key role in analyzing and developing the supply partner network in order to meet the demands of iSpecimen’s rapidly expanding customer base.

Eric has amassed nearly 20 years of experience in the arena of preclinical sample collections and biobanking for translational research.  Before joining iSpecimen, Eric was Head of North American Sales for the ReproCell Group.  He helped build and manage a sales team driven by the demands of integrating four portfolio companies with products and services in Cellular Reprogramming, Stem Cells, 3D cell culture, and biospecimens.  Prior to that, he held rapidly increasing positions from Regional Sales Manager to VP of Sales with Genomics Collaborative, SeraCare Life Sciences, SeqWright, and BioServe.  For over a decade Eric and his teams have proven quite successful at driving revenue using a consultative, customer-centric approach.  Eric holds a BS in Biotechnology/Biochemistry from Worcester Polytechnic Institute.

Dawn Michelle

Dawn Michelle

Vice President of Operations

Dawn Michelle

Dawn Michelle

Vice President of Operations

Dawn and her team manage all aspects of daily operations at iSpecimen, from understanding researcher requirements through fulfillment, working closely with iSpecimen’s network of partner laboratories and biorepositories.

Dawn has over 25 years of clinical laboratory management experience with an emphasis on regulatory oversight. Dawn was formerly the Director of Operations for the Partners Biorepository for Medical Discovery, where she was responsible for providing the Partners research community with a repository and related services to support clinical, translational, and basic science research programs. Prior to that she was on the management team at the Brigham and Women’s Hospital blood transfusion service where she managed day-to-day activities and special initiatives including the implementation of a new laboratory information system.

During her time at Brigham and Women’s Hospital, she sat on the AABB Immunohematology Reference Laboratories Standards Committee. She was a committee member for the 4th and 5th edition of standards and committee chair for the 6th edition of standards.

She received a BS in Clinical Laboratory Science from Georgia State University earning MT(ASCP) certification. Later, she earned a Specialist in Blood Banking (SBB) certification. She holds an MS in Computer Information Systems from Boston University as well as Lean Six Sigma Black Belt Certification from Villanova University.

 

Emily-Hubbard

Emily Hubbard

Vice President of Site Management & Development

Emily-Hubbard

Emily Hubbard

Vice President of Site Management & Development

Emily leads the Site Development and Management Team at Specimen. The team works with clinical sites to identify and audit clinical partners, facilitate agreements, implement workflow and compliance measures as well as ongoing oversight of sites and protocols. This allows iSpecimen to access specimens from  patient populations our researchers require for their work.

Emily has worked in Life Sciences for 20 years. Her career began in molecular biology. She moved quickly from the lab into management of Technical and Customer Support and Sales for companies such as Research Genetics, Invitrogen/Life Technologies and Thermo Fisher Scientific. Emily shifted into clinical research six years ago managing a team of Clinical Research Coordinators as well as management of relationships at a vast network of Clinical Sites. She joined iSpecimen in 2016, based in Huntsville, AL.

carly-lejnieks of iSpecimen

Carly Lejnieks

Vice President of Marketing

carly-lejnieks of iSpecimen

Carly Lejnieks

Vice President of Marketing

Carly and her team are focused on bringing the unique iSpecimen offering to life science customers who are seeking streamlined, compliant solutions for procuring archived pathology, banked, and prospective or custom-collected human biospecimens. The team is also focused on engaging new partners interested in joining the iSpecimen network, enabling deep and far-reaching access to millions of human biospecimens and patients that have consented to donate them.

Carly has led marketing strategies, integrated programs, and high-growth initiatives for Life Science organizations for more than 20 years. Before joining iSpecimen, she worked as a marketing consultant for more than a decade serving clients in the healthcare and life science industries. Most recently, she managed global, digital marketing and eCommerce programs responsible for driving double-digit growth in the cell culture consumables division of Thermo Fisher Scientific.

Evan Cox

Vice President of Product Management

Evan Cox

Vice President of Product Management

Evan brings nearly 20 years of Product Management and leadership experience to iSpecimen.  In his role at iSpecimen, Evan is responsible for creation and management of the long-term roadmap and strategy plan for our industry leading iSpecimen Marketplace application.  Prior to joining iSpecimen, Evan held several key senior management roles at Definitive Healthcare Corp., a provider of healthcare commercial intelligence, most recently as Associate Vice President, where he led the product management team. Before that, he held multiple product strategy and decision support roles at Change Healthcare, a healthcare technology company, where he focused on artificial intelligence and natural language processing to streamline existing workflows.

In addition, Mr. Cox co-founded DSE Analytics, a company that used natural language processing to integrate qualitative and quantitative information available on Consumer Assessment of Healthcare Providers and Systems (CAHPS) surveys to deliver providers deep insights into their satisfaction scores. He also served as Senior Product Manager of Data Analytics and Research at Press Ganey Associates and Product Lead of Clinical Data Management at WebMD.

Board of Directors

In addition to our Founder & CEO, Christopher Ianelli and our COO, Jill Mullan, the following individuals sit on iSpecimen’s board of directors:

Andrew Ross

Board Member

Andrew Ross

Board Member

Andrew is a lifelong entrepreneur and private investor with a focus on early stage investments in biotechnology, collaborative consumption, and cause-focused enterprise.

George “Bud” Scholl

Board Member

Bud has been an entrepreneur for most of his professional life.  He has primarily focused on purchasing and working out distressed assets across a variety of industries and asset types. He has developed and invested in financial, real estate, service and technology companies. Bud currently serves as the President and Chief Executive Officer of OneBlood, which was formed in 2012 as a result of a merger he organized, when he was Chairman and CEO of the Community Blood Centers of Florida, one of the three largest blood centers in the southeastern United States. Bud also currently serves as the mayor of the City of Sunny Isles Beach, Florida, where he was elected in 2014 after serving as City Commissioner for seven years. Bud is a graduate of the University of Florida and holds an engineering degree in computer science. In his leisure time, Bud enjoys skiing, boating, restoring old games, and playing guitar.

Steven Gullans

Board Member

Steven Gullans

Board Member

Steven Gullans has been serving as our director since October 2020. Mr. Gullans serves as a Class I Director and his current term will expire at our 2023 annual meeting of stockholders. From May 2018 to December 2019, he served as President and Chief Executive Officer and Director of Gemphire Therapeutics, until it was acquired by NeuroBo Pharmaceuticals. While at Gemphire, he oversaw activities related to clinical trials, manufacturing, finances, business development, R&D and intellectual property. Prior to Gemphire, he was Managing Director at Excel Venture Management, LLC (“Excel”), a Boston-based venture capital firm which he co-founded, from March 2008 to May 2018. At Excel, he focused on investing in life science technology companies with a particular interest in disruptive platforms that can impact multiple industries. Prior to Excel, Dr. Gullans co-founded RxGen, Inc., a pharmaceutical services company, where he also served as Chief Executive Officer and a director from February 2004 to February 2008. Prior to that, he was the Chief Scientific Officer of US Genomics, Inc., a company that developed technology to analyze DNA for pathogen detection, from November 2002 to January 2004. Dr. Gullans currently serves as a director at Orionis Biosciences, Atentiv Health, Navigation Sciences, and Alexis Bio. He was previously a board member of Activate Networks, Inc. which was acquired by Decision Resource Group, nanoMR Inc., which was acquired by DNA Electronics Ltd, Tetraphase Pharmaceuticals, Inc. which went public in 2013, and Molecular Templates, Inc. which was merged into a public entity in 2017, BioTrove which was acquired by Agilent, and NeuroBo Pharmaceuticals. Dr. Gullans was a faculty member at Harvard Medical School and Brigham and Women’s Hospital for almost 20 years. Dr. Gullans holds a B.S. from Union College and a Ph.D. from Duke University. He is well-qualified to serve on our Board due to his extensive experience in biopharmaceutical industries and his expertise in medical and pharmaceutical research.

John L. Brooks III

Board Member

John L. Brooks III

Board Member

John L. Brooks III has been serving as our director since the date hereof. Mr. Brooks serves as a Class II Director and his current term will expire at our 2023 annual meeting of stockholders. He currently also serves as a director of Hemoshear Therapeutics since November 2008, Noxilizer since March 2009, Hygieia since June 2016 and Atentiv since March 2020. He also serves as the chairman of Thermalin, Inc. since January 2009. Mr. Brooks is also the President of the NTT division of L-Nutra Inc, a company focused on nutrition and fasting mimicking technologies since March 2021. In January 2012, Mr. Brooks founded Ammonett Pharma and continues to serve on its board of directors since then. He has also served as the managing director of Healthcare Capital LLC since February 2007. Previously, Mr. Brooks served as the Chief Executive Officer, President and a director of NeuroBo Pharmaceuticals, Inc. from March 2018 to December 2019 and as the chairman of Cellnovo, Ltd. from 2012 to December 2019. Mr. Brooks is also involved with several non-profit organizations. He currently serves as the Chief Executive Officer and President of Worldwide Network for Innovation in Clinical Education and Research (WNICER) since January 2019 and also serves as a director of T1D Exchange since March 2020, the ADA New England Chapter since January 2015, Population Health Alliance since January 2014, and the University of Massachusetts Amherst Foundation since January 2012. He also chairs the College Diabetes Network since January 2011. Mr. Brooks received his BBA and MSBA in Accounting from the University of Massachusetts Amherst. He is well-qualified to serve on our Board due to his expertise in healthcare and life sciences.

Christopher Ianelli, MD, PhD

Board Member

Chris conceptualized and founded iSpecimen in response to the precision medicine movement and the growing demand for biospecimens by life science researchers where he served as the CEO until October 2022. Prior to launching iSpecimen, Chris served as Managing Director at Leerink Partners (formerly Leerink Swann), a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm. At Leerink, Chris launched Health Insight Technologies, a healthcare informatics company that was spun out of the firm as Humedica and acquired by UnitedHealth Group in 2013.

Prior to Leerink, Chris was a co-founder and Managing Director of Boston Medical & Scientific Advisors, a healthcare investment research firm ultimately acquired by Leerink. He received both his Ph.D. in Immunology and his M.D. from Tufts University and completed his residency training, including a year as Chief Resident, in Pathology at Brigham & Women’s Hospital and Harvard Medical School.

Jill Mullan

Board Member

Jill Mullan

Board Member

Jill has over 30 years of experience in operational management, strategy, and marketing. Prior to joining the iSpecimen Board of Directors, Jill served as the Chief Operating Officer for iSpecimen until October 2022. Before joining iSpecimen, she ran a consulting business to help companies develop business and product strategies, raise funds, create brands, and launch new products. Prior to that, Jill was on the founding team and Director of Marketing at Storigen Systems, where she built and ran the company’s marketing organization, developed the company’s brand identity, and launched several successful products. She was also the Director of Product Marketing and Management at Avid Technology, managing the P&L for Avid’s $400M editing product line. Jill graduated with distinction from Cornell University with a BS in electrical engineering and received her MBA from Stanford University.

Advisors

Robert Babkowski, MD, FCAP

Chair of Pathology, Stamford Hospital

Martin Ferguson, PhD

Consultant, National Cancer Institute

Bill O’Donnell

Chief Executive Officer, Blade

Ed Trautman, PhD

VP, Informatics, Analytics and Business Intelligence LabCorp

Jim Vaught, PhD

Editor in Chief, Biopreservation & Biobanking Journal